Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab

摘要: ABSTRACTIntroduction: Trastuzumab, a therapeutic monoclonal antibody directed against ErbB2, is often noted as successful example of targeted therapy. Trastuzumab improved outcomes for many patients with ErbB2-positive breast and gastric cancers, however, cardiac side effects [e.g., left ventricular dysfunction congestive heart failure (CHF)] were reported in the early phase clinical studies. This finding, subsequently corroborated by multiple studies, raised concerns that observed cardiotoxicity induced trastuzumab might adversely impact development other therapeutics targeting ErbB family members.Areas covered: In this review we summarize both basic research findings regarding trastuzumab-induced assess if there has been an on agents members.Expert opinion: There are number scientific gaps critically important to address c...